ALK receptor tyrosine kinase gene (ALK) rearrangement is a common driver mutation for patients with NSCLC. At present, more than 20 fusion partners for ALK in NSCLC have been reported. The most common partner of ALK rearrangement is echinoderm microtubule-associated protein-like 4 gene (EML4). But ALK double fusion is rare. ALK inhibitors are widely used in cancer-targeted therapy now. The progression-free survival of patients with ALK-positive NSCLC treated with alectinib as a first-line treatment is varied due to different fusion forms of ALK [ [1] ]. Therefore, it is of great clinical significance to continuously explore new forms of ALK fusion and study its correlation with drug sensitivity. With the development of next-generation sequencing (NGS) technology, ALK detection is becoming more and more precise, Herein we described a patient with advanced lung adenocarcinoma who presented simultaneously with two novel fusions, EML4-ALK and BIRC6-ALK, and with sensitivity to alectinib. READ ARTICLE
Lung Cancer DOI:10.1016/j.lungcan.2020.04.030
Authors: Jiang-Ming Zhong, Gui-Feng Zhang, Li Lin, De-Yu Li, Zhen-Hua Liu